SLC4A4 is a novel driver of enzalutamide resistance in prostate cancer. Chen HJ, Yu MM, Huang JC, Lan FY, et al. Cancer Lett 2024 Jun 14:217070. doi: 10.1016/j.canlet.2024.217070.

Read + Share

Amedeo Smart

Independent Medical Education

Chen HJ, Yu MM, Huang JC, Lan FY, et al. SLC4A4 is a novel driver of enzalutamide resistance in prostate cancer. Cancer Lett 2024 Jun 14:217070. doi: 10.1016/j.canlet.2024.217070.
PMID: 38880227